The objective of this study is to determine the safety and feasibility of autologous
mononuclear cells (MNS) collected from bone marrow (BM) and using an add-on intramyocardial
delivery for individuals with Ebstein anomaly undergoing surgical intervention compared to
the control group undergoing the same surgical procedure without cell delivery. This add-on
procedure has the potential to foster a new strategy for individuals with congenital heart
disease.This is an open-label study of autologous MNC derived from bone marrow with a 2-year
follow-up to document 1) incidence and severity of adverse event and 2) monitor changes in
cardiac structure and function.